A Trans-Nasal Aerosol Delivery Device for Efficient Pulmonary Deposition
| Autor: | Scott H. Donaldson, Juan Rojas Balcazar, Fred Fuller, William D. Bennett, Karl H. Donn, Richard C. Boucher, Kirby L. Zeman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Pulmonary and Respiratory Medicine Materials science Pharmaceutical Science medicine.disease_cause complex mixtures 030226 pharmacology & pharmacy Pulmonary deposition 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Nasal Aerosol Administration Inhalation medicine Cannula Humans Tissue Distribution Pharmacology (medical) Particle Size Lung Administration Intranasal Mouthpiece Original Research Aerosols Saline Solution Hypertonic Cross-Over Studies Nebulizers and Vaporizers Masks Equipment Design respiratory system Rainout Aerosol Hypertonic saline 030228 respiratory system Anesthesia Technetium Tc 99m Pentetate Radiopharmaceuticals Nasal cannula Biomedical engineering |
| Zdroj: | Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30:223-229 |
| ISSN: | 1941-2703 1941-2711 |
| DOI: | 10.1089/jamp.2016.1333 |
| Popis: | Efficient delivery of aerosols to the lungs via the nasal route has been difficult to achieve, but it may offer benefits over the traditional oral route for a range of patient populations. Because slow, continuous delivery of short-acting agents could improve safety, tolerability, compliance, and efficacy when compared with the rapid, intermittent aerosol treatments delivered by mouthpiece or mask, a novel trans-nasal pulmonary aerosol delivery (tPAD) device was developed. The tPAD incorporates an aerosol particle-size selection chamber and a custom nasal cannula that are specifically optimized for aerosol delivery to the lung via the nasal route. The tPAD device produced a steady aerosol output (∼2 mL/h) from an optimized nasal cannula with negligible rainout in the cannula for up to 8 hours. The generated aerosol particles were small enough to minimize nasal deposition [volume median diameter (VMD) = 1.4 μm].In this proof-of-concept study, gamma scintigraphy was used to quantitate deposition efficiency ofThe tPAD device achieved high pulmonary deposition (39% ± 8%), based on emitted dose, and matched that of the oral jet nebulizer (36% ± 9%). Low fractions of aerosol deposition in the head and nose region were observed for tPAD (6% ± 6%) and jet nebulizer deliver (1% ± 1%) as well.A profile of high pulmonary deposition efficiency and low nasal dose may enable the sustained use of the tPAD platform with a variety of therapeutic agents for a range of pulmonary disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|